Blog: A new data aims to help AI work better for biotech — and it’s free – STAT
Artificial intelligence is the hot new thing in drug discovery and development. AstraZeneca, Pfizer, and Merck have all relied on machine learning to advance their research. Bristol-Myers Squibb and Boston-based Concerto HealthAI established a new partnership in March. And Relay Therapeutics raised an astonishing $400 million series C round to support its efforts to use AI techniques to understand the way proteins bend and twist and create new drugs.
But if artificial intelligence programs are actually going to make an impact, they’re going to need a lot of data — and high quality data is hard to come by. Currently available data sets aren’t ideal for machine learning, and relying on that data might even set certain algorithms down the wrong path.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
What is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
General Assignment Reporter
Kate is a general assignment reporter.